Gilead is in-licensing investigational molecules for influenza, rhinovirus and herpes. Novartis will receive an upfront payment and an additional $291 million in milestones.
Iterum Therapeutics, based in Ireland but financed in the U.S., is comprised largely of the team that launched Durata Therapeutics - which was acquired two years ago by Actavis for $675 million.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.